Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

in the third quarter of 2008 from this study.

The CEA study is designed to evaluate the efficacy of VIA-2291 in the vessel wall, and has the unique advantage of providing access to atherosclerotic tissue for direct evaluation of VIA-2291's effect on inflammation, through a panel of assays and histological examinations.

Acute Coronary Syndrome (ACS) Study

The ACS study has enrolled more than two-thirds of the targeted 200 patients for this trial and top-line data results are anticipated to be released shortly after the release of data from the CEA trial. This study is designed to establish dose and safety data in patients with acute coronary syndrome (ACS) who have experienced a recent heart attack, and includes measures of leukotrienes, biomarkers of inflammation as well as medical imaging of the coronary vessel wall to evaluate impact on plaque characteristics.

About VIA-2291

VIA-2291 is a selective and reversible inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). Potentially a complement to current standard of care therapies that treat risk factors, such as statins, antiplatelet and blood pressure medications, VIA-2291 is initially targeted to address the secondary prevention market for patients who have already suffered a major adverse cardiovascular event, but eventually could be beneficial to the broader 15.8 million patients in the U.S. who have coronary artery disease. VIA has exclusive worldwide rights to develop and commercialize VIA-2291. Based upon prior trials of VIA-2291 in more than 1,100 patients, VIA believes that VIA-2291 will be safe and well tolerated in doses currently being administered in the ongoing clinical trials.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovas
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)... Reduce Animal Use in Cosmetics and Chemicals Test...k Corp. today announced,that results of a recently...-up" validation study on MatTek,s EpiDerm in vitro...monstrated the required sensitivity and,specificit...ative to animal,testing for determining human skin...
(Date:10/8/2008)...nstitute Pioneers Research That May Offer New Hope...wswire/ -- Nationally, over 3,000 people are,waiti...e. Sadly, only half,of those will receive a transp...stitute (AHI) is paving the way for how to treat c...the Multimedia News Release, go to:, http://www.pr...
(Date:10/8/2008)...rsity Food Scientists Expand Testing Using Cellula..., PORTLAND, Maine, Oct. 8 /- Wild Bl...he release of results from a new study,showing Wil...consumed,fruits like apples, bananas, red grapes a...ular Antioxidant Activity (CAA) assay. New researc...
(Date:10/8/2008)...Confirm Potency of Poly-ICR as Vaccine Adjuvant, ... Biopharmaceuticals,Corporation (TSX: NVN) today p...ing its proprietary Toll-like Receptor 3 agonist, ...cine Congress 2008 in Lyon, France.,Study results ...ant,targeting the Toll-like Receptor 3 (TLR3) path...
Breaking Medicine Technology:MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Hurried doctor visits may leave patients feeling forgetful 22772 1Hurried doctor visits may leave patients feeling forgetful 22772 2Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 1Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 2Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 3Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 4Christine Poon Will Keynote MichBio Expo 6210 1Christine Poon Will Keynote MichBio Expo 6210 2Christine Poon Will Keynote MichBio Expo 6210 3 TraumaCure Receives Prestigious ISO 13485 Certification 6209 1 TraumaCure Receives Prestigious ISO 13485 Certification 6209 2
...d today shows reduction of 70,percent in spine fra...ER, N.J., May 02, 2007 /PRNewswire/ -- A once-year...tion significantly,reduced the incidence of all ty...s in women with postmenopausal osteoporosis. This,...of Medicine,marks the first time that an osteopor...
...- Bayer HealthCare,Pharmaceuticals announced today...ron(R) (interferon beta-1b), presented this week,a...nnual Meeting,demonstrating early efficacy, long-...ith treatment in patients with relapsing,forms of ...udies highlight the important clinical,benefits an...
Other Medicine Technology:Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 2Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 3Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 4Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 6Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 2Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 3Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 4
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...fare, Indian scientists have been sequencing the g...It is India's first sequencing effort of a complet...several diseases, including tuberculosis and lepro...de from killed Mw drastically reduces treatment ti...
...fer from migraine are more at risk of heart attack...ological condition, of which the most common sympt... Men with migraines were more likely to have high...d cholesterol levels, compared to men who didn't h...
...a bacterium, which is one of the leading cause for...ing cause for blindness globally, is said to be// ...ve imagined. The scientists from Children’s Hospi...ere the first to conclude this with the help of a ...
...two important changes that revolve around prematur...ch-greater ability of medical advances to keep// a...nge that has been noted is the increased rate of p...e births resulting from fertility treatment. A re...
Other Medicine News:Health News:India Finds New Use for an Old Bug 2Health News:India Finds New Use for an Old Bug 3Health News:Newly Identified Strains Of Chlamydia Trachomatis – A Gateway To New Disease 2Health News:Premature Babies- What should be done about them? 2
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: